Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Spice maker, McCormick & Company, Inc. ( MKC - Analyst Report ) is all set to report its fiscal third quarter 2012 results before the market opens on September 27, 2012. The Zacks Consensus Estimate for the third quarter is pegged at 76 cents (estimated year-over-year increase of 10.2%) on revenues of $991 million (year-over-year increase of 7.7%).
Second Quarter Recap
McCormick delivered strong second quarter 2012 earnings of 60 cents, which beat the prior-year quarter’s earnings by 9%. The results were driven by favorable operating income and tax rate, offset by lower income from unconsolidated operations and higher interest expense. Earnings in the quarter, however, lagged the Zacks Consensus Estimate by a penny.
Total revenue in the quarter grew 11% year over year to $984 million. Revenue also exceeded the Zacks Consensus Estimate of $968.0 million. On a constant currency basis, revenue increased 13%, half of which was contributed by acquisitions completed in 2011. McCormick’s price increase in response to high input costs, volume growth and favorable product mix also contributed to the overall revenue growth.
Agreement of Estimate Revisions
There has been no estimate revision for the current quarter or the fiscal year over the last 7 days. However, over the last 30 days, 1 of 13 estimates has moved up for the fiscal 2012. None of the estimates has been revised downwards. There has been no estimate revision for the current quarter over the last 30 days.
Magnitude of Estimate Revisions
Given the limited estimate revisions, the consensus estimates for the third quarter as well as for full year 2012 have remained static over the last 7 as well as 30 days at 76 cents and $3.05, respectively.
At the second quarter conference call, management had maintained its sales and earnings guidance which was again later reaffirmed at an investor conference held in early September. There have been no major new updates since then, which explain the lack of estimate revisions.
Surprise History
Over the past four quarters, McCormick has surpassed estimates thrice and missed once, thereby resulting in an average earnings estimate of 3.62%. The company recorded a maximum positive surprise of 6.19% in the fourth quarter of 2011.
Our Recommendation
McCormick, which competes with ConAgra Foods, Inc. ( CAG - Analyst Report ) and Kraft Foods Inc. ( ) , currently has a Neutral recommendation. The stock carries a Zacks #3 Rank (a short-term ‘Hold’ rating).
Read the full reports :
Analyst Report on CAG
Analyst Report on MKC